Precision Biosciences (DTIL) Free Cash Flow (2018 - 2026)

Precision Biosciences (DTIL) has reported Free Cash Flow for 9 consecutive years, with -$12.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Free Cash Flow rose 37.46% year-over-year to -$12.0 million; the TTM figure through Mar 2026 stood at -$58.8 million (changed 0.04% YoY), while the FY2025 annual figure was -$65.9 million, down 12.32% from the prior year.
• Free Cash Flow retreated to -$12.0 million in Q1 2026 per DTIL's latest filing, from -$11.3 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $28.1 million in Q3 2022 and bottomed at -$32.0 million in Q1 2023.
• Historically, Free Cash Flow has averaged -$16.0 million across 5 years, with a median of -$19.1 million in 2024.
• Annual changes were most pronounced in 2022 — Free Cash Flow jumped 214.04% — and 2023, when it sank 183.57%.
• Precision Biosciences' Free Cash Flow stood at -$22.5 million in 2022, then surged by 62.64% to -$8.4 million in 2023, then sank by 123.65% to -$18.8 million in 2024, then soared by 39.99% to -$11.3 million in 2025, then declined by 6.09% to -$12.0 million in 2026.
• Business Quant data shows DTIL's Free Cash Flow at -$12.0 million in Q1 2026, -$11.3 million in Q4 2025, and -$15.3 million in Q3 2025.